New directions for erectile dysfunction therapies

International Journal of Impotence Research

Volumn 14, Issue , 2002, Pages S82-S92

  Andersson, Karl Erik ^a   Hedlund, P ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Combination therapy; Erectile dysfunction; Gene therapy; Phosphodiesterase inhibitors; Prevention

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; ARGININE; DOPAMINE RECEPTOR BLOCKING AGENT; EP 50885; EP 60761; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; GUANYLATE CYCLASE; HEXARELIN; LISURIDE; MELANOCORTIN RECEPTOR; MELANOTAN II; MOXISYLYTE; NITRIC OXIDE; OXYTOCIN; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PIRIBEDIL; PRAZOSIN; QUINELORANE; RHO KINASE; SEROTONIN 2C AGONIST; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; YOHIMBINE;

CLINICAL TRIAL; CONFERENCE PAPER; CORPUS CAVERNOSUM; DROWSINESS; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; GENE THERAPY; HUMAN; LACRIMATION; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; VERTIGO; VOMITING; YAWNING;

GENE THERAPY; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS;

EID: 0036194396     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900797     Document Type: Article

References (89)

1. Current research and future therapies
2. Pharmacology of erectile function and dysfunction
3. Expression of different phosphodiesterase genes in human cavernous smooth muscle
4. Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis
5. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction
6. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum
7. Vardenafil: Update on clinical experience
8. IC351 (tadalafil, Cialis): Update on clinical experience
9. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs
10. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159
11. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum
12. Physiology of penile erection
13. Apomorphine: Clinical studies on erectile impotence and yawning
14. Recovery of erectile function by the oral administration of apomorphine
15. Apomorphine: An update of clinical trial results
16. The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat
17. Sympathetic pathways and adrenergic innervation of the penis
18. Human cloned alpha1 A-adrenoceptor isoforms display alpha1 L-adrenoceptor pharmacology in functional studies
19. 1L-adrenoceptor mediates contraction in human erectile tissue
20. 1A-adrenoceptor antagonist in the treatment of male erectile dysfunction
21. Effects of intracavernous administration of selective antagonists of alpha(1)-adrenoceptor subtypes on erection in anesthetized rats and dogs
22. Subtyping of alpha1-adrenoceptors responsible for the contractile response in the rat corpus cavernosum
23. Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue
24. 1
25. Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence
26. Combination of phentolamine and L-arginine or sildenafil synergistically improves neurogenic relaxation of rabbit corpus cavernosum smooth muscle
27. ACTH- and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: Site of action in the brain and role of melanocortin receptors
28. Melanocortin receptors: Perspectives for novel drugs
29. New aspects on the melanocortins and their receptors
30. Differential influence of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioral effects in rats
31. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study
32. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction
33. Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II
34. Oxytocin: An extremely potent inducer of penile erection and yawning in male rats
35. Oxytocin stimulation of penile erection: Pharmacology, site, and mechanism of action
36. Oxytocinergic neurotransmission at the hippocampus in the central neural regulation of penile erection in the rat
37. Paraventricular nucleus lesion prevents yawning and penile erection induced by apomorphine and oxytocin, but not ACTH 1-24
38. 8-vasotocin, a potent oxytocin antagonist, antagonizes penile erection and yawning induced by oxytocin and apomorphine, but not by ACTH (1-24)
39. Apomorphine- and oxytocin-induced penile erection and yawning in intact and castrated male rats: Effects of sexual steroids
40. Oxytocin-induced penile erection and yawning: Role of calcium and prostaglandins
41. Apomorphine- and oxytocin-induced penile erection and yawning in male rats: Effect of pertussis toxin
42. Nitric oxide synthase inhibitors prevent apomorphine- and oxytocin-induced penile erection and yawning in male rats
43. Penile erection and yawning induced by paraventricular NMDA injection in male rats are mediated by oxytocin
44. Nitric oxide synthase inhibitors prevent N-methyl-D-aspartic acid-induced penile erection and yawning in male rats
45. Growth hormone-releasing peptides
46. Endocrine and non-endocrine activities of growth hormone secretagogues in humans
47. Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release
48. EP 60761- and EP 50885-induced penile erection: Structure-activity studies and comparison with apomorphine, oxytocin and N-methyl-D-aspartic acid
49. Penile erection induced by EP 80661 and other hexarelin peptide analogues: Involvement of paraventricular nitric oxide
50. EP 60761 and EP 50885, two hexarelin analogues, induce penile erection in rats
51. Pharmacological analysis of male rat sexual behavior
52. Neural control of penile erection
53. A review of central 5-HT receptors and their function
54. Autoradiographic mapping of 5-HT1, 5-HT1A, 5-HT1B and 5-HT2 receptors in the rat spinal cord
55. Autoradiographic localization of 5-hydroxytryptamine1A, 5-hydroxytryptamine1B and 5-hydroxytryptamine1C/2 binding sites in the rat spinal cord
56. Direct immunocytochemical localization of 5-hydroxytryptamine receptors in the adult rat spinal cord: A light and electron microscopic study using an anti-idiotypic antiserum
57. Intracavernous pressure responses to physical and electrical stimulation of the cavernous nerve in rats
58. 5-Hydroxytryptamine2C receptors on spinal neurons controlling penile erection in the rat
59. Novel agonists of 5HT2C receptors: Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1, 2-b]pyrrol-1-yl)-1-methylethylamines: Improved therapeutics for obsessive compulsive disorder
60. Pro-erectile effects of novel serotonin agonists
61. Guanylyl cyclases and signaling by cyclic GMP
62. Presence and biological activity of C-type natriuretic peptide-dependent guanylate cyclase-coupled receptor in the penile corpus cavernosum
63. Membrane bound guanylyl cyclases in human corpus cavernosum: Expression and functional relevance
64. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators
65. Human recombinant soluble guanylyl cyclase: Expression, purification, and regulation
66. Mechanism of YC-1-induced activation of soluble guanylyl cyclase
67. NO-independent regulatory site on soluble guanylate cyclase
68. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase
69. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets
70. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: Synergism of nitric oxide and YC-1
71. NO-independent activation of guanylate cyclase in vitro and in vivo by YC-1 in the rat corpus cavernosum
72. Calcium movements, distribution, and functions in smooth muscle
73. Physiological features of visceral smooth muscle cells, with special reference to receptors and ion channels
74. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II
75. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway
76. RhoA/Rho-kinase: A novel player in the regulation of penile erection
77. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum
78. Gene therapy strategies for urological dysfunction
79. Potential application of gene therapy for the treatment of erectile dysfunction
80. Integrative erectile biology: The effects of age and disease on gap junctions and ion channels and their potential value to the treatment of erectile dysfunction
81. Cloning of rat and human inducible penile nitric oxide synthase: Application for gene therapy of erectile dysfunction
82. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function
83. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat
84. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat
85. Vascular risk factors and erectile dysfunction
86. Vascular endothelial growth factor restores corporeal smooth muscle function in vitro
87. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: A preliminary study
88. Modifiable risk factors and erectile dysfunction: Can lifestyle changes modify risk?
89. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes: Epibatidine analogues